** Shares of drug developer Keros Therapeutics KROS.O fall ~71% to $20 premarket
** KROS says it has halted dosing of 3.0 mg and 4.5 mg doses of its high blood pressure treatment in a mid-stage study due to fluid buildup around the heart
** Dosing in the 1.5 mg/kg arm will continue after a risk-benefit review by an independent monitoring committee - KROS
** Co has notified the U.S. FDA about it and expects to present data from all treatment arms in Q2 2025 - KROS
** As of last close, stock has fallen 25.7% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.